MedTrace Logo

Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults

NCT04227210 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-09-16

No results posted yet for this study

Summary

This study evaluates an investigational vaccine designed to protect humans against infection with respiratory syncytial virus (RSV). The investigational vaccine (MV-012-968) is administered as drops in the nose. This study specifically analyzes the safety of, and the immune response to, the vaccine when administered to healthy non-pregnant adults between the ages of 18 and 40 years.

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL

RSV vaccine MV-012-968 (dosage #1)

Single dose administered intranasally on Day 1

BIOLOGICAL

RSV vaccine MV-012-968 (dosage #2)

Single dose administered intranasally on Day 1

Sponsors & Collaborators

  • Meissa Vaccines, Inc.

    lead INDUSTRY

Principal Investigators

  • Oliver Medzihradsky, MD MPH MS · Meissa Vaccines, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-14
Primary Completion
2020-08-27
Completion
2020-08-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04227210 on ClinicalTrials.gov